The characterisation of molecular abnormalities in patients with lung cancers has led to the development of a number of targeted therapies, mainly based on mutations in the EGFR, ALK or KRAS genes
Authors
Others publications
Genomics
Pharmacogenetics and pharmacogenomics
Diabetes
Alternative macrophages in vascular calcification: what is their role in type 2 diabetic subjects?
The patient
Complex situations: the example of renal transplantation
Oncology
Radiological-pathological correlations in lung adenocarcinoma: qualitative and quantitative approaches